Protein Formulation
AssigneeOne Medimmune Way
InventorsMonika S. Sharma, SR., Ambarish Shah, Scott Hammond
Life of this patent
Estimating the term…
Abstract
The present invention provides stable lyophilized formulations of bispecific antibodies or fragments thereof.
Claims30
A liquid pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.
(canceled)
(canceled)
8-11. (canceled)
13-29. (canceled)
A lyophilized pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.
(canceled)
The formulation of claim 3035, wherein the formulation further comprises one or more of:
- a) a buffering agent chosen from histidine, citrate, phosphate, glycine, and acetate;
- b) a carbohydrate chosen from sucrose, trehalose, lactose, mannitol, and raffinose;
- and
- c) a surfactant chosen from Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.
37-43. (canceled)
A liquid reconstituted pharmaceutical formulation comprising a bispecific antibody and lysine, wherein the bispecific antibody comprises first and second binding domains, wherein the first binding domain specifically binds the CD3 T cell surface antigen.
(canceled)
50-52. (canceled)
54-72. (canceled)
74-75. (canceled)
Dependencies are inferred from the claim text.